Gene signatures revisited

Journal of the National Cancer Institute

Volumn 104, Issue 4, 2012, Pages 262-263

  Baker, Stuart G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CARCINOGENESIS; EDITORIAL; GENE EXPRESSION; GENE MUTATION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

BREAST NEOPLASMS; FEMALE; HUMANS; MICROARRAY ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84857604394     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr557     Document Type: Editorial

References (19)

1. Haibe-Kains B, Desmedt C, Loi S, et al. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst. 2012; 104 (4): 311-325.
2. Geman D, d'Avignon C, Naiman DQ, Winslow RL. Classifying gene expression profiles from pairwise mRNA comparisons. Stat Appl Genet Mol Biol. 2004; 3: 19.
3. Baker SG. Simple and flexible classification via Swirls-and-Ripples. BMC Bioinformatics. 2010; 11: 452.
4. Wang X, Simon R. Microarray-based cancer prediction using single genes. BMC Bioinformatics. 2011; 12: 391.
5. Stratton MR, Campbell PJ, Futreal1 PA. The cancer genome. Nature. 2009; 458 (7239): 719-724.
6. Soto AM, Sonnenschein C. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays. 2011; 33 (5): 332-340.
7. Hand DJ. Classifier technology and the illusion of progress. Statist Sci. 2006; 21 (1): 1-14. (Pubitemid 44046906)
8. Dunkler D, Michiels S, Schemper M. Gene expression profiling. Does it add predictive accuracy to clinical characteristics in cancer progression? Eur J Cancer. 2007; 43 (4): 745-751. (Pubitemid 46502906)
9. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011; 17 (3): 320-329.
10. Baker SG. TOFT better explains experimental results in cancer research than SMT. Bioessays. 2011; 33 (12): 919-921.
11. Finak G, Sadakova S, Pepin F, et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res. 2006; 8: R58.
12. Chang HY, Sneddon JB, Alizadeh AA. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004; 4 (2): 206-214.
13. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006; 26 (6): 565-574. (Pubitemid 44728772)
14. Baker SG. Putting risk prediction in perspective: relative utility curves. J Natl Cancer Inst. 2009; 101 (22): 1538-1542.
15. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010; 102 (3): 152-160.
16. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res. 2005; 11 (21): 7872-7878. (Pubitemid 41611633)
17. Vickers AJ, Kattan MW, Sargent DJ. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials. 2007; 9: 14.
18. Cai T, Tian L, Wong PH, Wei LJ. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics. 2011; 12 (2): 270-282.
19. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med. 2000; 19 (19): 2595-2609.